Black Rock Inc. Talaris Therapeutics, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.68 - $3.22 $9,535 - $11,456	-3,558 Reduced 2.73%	126,831 $356,000
Q2 2023 Aug 11, 2023	SELL	$1.78 - $3.2 $1.84 Million - $3.31 Million	-1,034,478 Reduced 88.81%	130,389 $396,000
Q1 2023 May 12, 2023	BUY	$1.09 - $2.09 $71,200 - $136,522	65,322 Added 5.94%	1,164,867 $2.19 Million
Q4 2022 Feb 13, 2023	SELL	$0.94 - $1.64 $834,899 - $1.46 Million	-888,191 Reduced 44.68%	1,099,545 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$2.3 - $5.03 $1.23 Million - $2.68 Million	-532,869 Reduced 21.14%	1,987,736 $5.23 Million
Q2 2022 Aug 12, 2022	BUY	$4.51 - $9.85 $390,976 - $853,906	86,691 Added 3.56%	2,520,605 $11.4 Million
Q1 2022 May 12, 2022	BUY	$6.89 - $16.56 $264,913 - $636,715	38,449 Added 1.61%	2,433,914 $24 Million
Q4 2021 Feb 10, 2022	BUY	$12.18 - $17.0 $8.08 Million - $11.3 Million	663,633 Added 38.32%	2,395,465 $36.6 Million
Q3 2021 Nov 09, 2021	SELL	$11.61 - $15.99 $479,434 - $660,307	-41,295 Reduced 2.33%	1,731,832 $23.5 Million
Q2 2021 Aug 11, 2021	BUY	$12.25 - $18.61 $21.7 Million - $33 Million	1,773,127 New	1,773,127 $26 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.